 Home > Medical News > Latest Medical News > Two drugs to be included in breakthrough therapy varieties involve Fosun Kite, Mingju Bio

Two drugs to be included in breakthrough therapy varieties involve Fosun Kite, Mingju Bio

 Last Update: 2022-04-22
 Source: Internet
 Author: User

Tags

huh7 cell line

drugs therapy

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On March 24, the CDE official website recently revealed that Fosun Kite FKC889 and Mingju Bio’s JWCAR029 are planned to be included in breakthrough therapy varieties

It is reported that the proposed indication of FKC889 is relapsed/refractory mantle cell lymphoma, and the proposed indication of JWCAR029 is adult relapsed and refractory mantle cell lymphoma after second-line or above treatment

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.